BOSTON, March 17, 2011 /PRNewswire/ -- Experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will address best-practice strategic partnership models to increase operating efficiency and improve development effectiveness during the 20th Annual Partnerships in Clinical Trials conference, to be held March 30-April 1, 2011 in Phoenix, Arizona. Attendees can learn more about how PAREXEL has transformed its business to deliver a new level of strategic partnering, based on program design expertise, operational excellence, and project leadership to help clients achieve their development goals by visiting PAREXEL Booth #707 in the exhibit hall.
In two special presentations with Merck and Bristol-Myers Squibb, PAREXEL will discuss leveraging global resources and a worldwide technology infrastructure, as well as innovative approaches, to achieve significant value creation through strategic relationships:
eClinical Technology Track, March 31, 2:15 p.m.
The Evolution of CROs—Convergence of Service and Technology Providers will be presented by Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL with Lynne Germscheid, Account Management, Clinical and Regulatory Operations, Merck Research Laboratories Information Technology.
Strategic Sourcing Track, April 1, 11:00 a.m.
Committing to Two Partners—A Look at the BMS Integrated Strategic Sourcing Initiative will feature Joshua Schultz, Corporate Vice President and Strategic Account Leader, PAREXEL with Joan Millsaps, Director, Business Operations and Outsourcing Management and Cynthia Hauck, Associate Director, Outsourcing Management of Bristol-Myers Squibb.
The Partnerships in Clinical Trials program also features the following sessions by PAREXEL experts, which focus on achieving high levels of quality in clinical development to optimize outcomes:
About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,380 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2010 as filed with the SEC on February 9, 2011, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations
Kim Baker/Gene CarozzaPAREXEL International
PAN CommunicationsTel: +781-434-4409
Tel: + 978-474-1900Email: Jennifer.Baird@PAREXEL.com
|SOURCE PAREXEL International Corporation|
Copyright©2010 PR Newswire.
All rights reserved